Scholar Rock Holding Corporation

NasdaqGS:SRRK Stock Report

Market Cap: US$7.0b

Scholar Rock Holding Valuation

Is SRRK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SRRK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: SRRK ($54.62) is trading below our estimate of future cash flow value ($130.67)

Significantly Below Future Cash Flow Value: SRRK is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SRRK?

Key metric: As SRRK is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SRRK. This is calculated by dividing SRRK's market cap by their current book value.
What is SRRK's PB Ratio?
PB Ratio26.2x
BookUS$253.78m
Market CapUS$6.99b

Price to Book Ratio vs Peers

How does SRRK's PB Ratio compare to its peers?

The above table shows the PB ratio for SRRK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average23.7x
CGON CG Oncology
6.2x61.97%US$6.5b
CAI Caris Life Sciences
11.5x27.98%US$7.0b
RYTM Rhythm Pharmaceuticals
67.6x69.76%US$7.0b
KNSA Kiniksa Pharmaceuticals International
9.4x37.97%US$6.0b
SRRK Scholar Rock Holding
26.2x47.95%US$7.0b

Price-To-Book vs Peers: SRRK is expensive based on its Price-To-Book Ratio (26.2x) compared to the peer average (23.7x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does SRRK's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
CNTN Canton Strategic Holdings
0.4xn/aUS$177.69m
FRMM Forum Markets
0.5x127.09%US$64.01m
IMA ImageneBio
0.4x-32.04%US$57.32m
TIL Instil Bio
0.5xn/aUS$53.04m
SRRK 26.2xIndustry Avg. 2.5xNo. of Companies79PB0246810+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: SRRK is expensive based on its Price-To-Book Ratio (26.2x) compared to the US Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is SRRK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SRRK PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio26.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SRRK's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SRRK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$54.62
US$60.75
+11.22%
9.73%US$76.00US$48.00n/a16
Sep ’27US$55.89
US$60.75
+8.70%
9.73%US$76.00US$48.00n/a16
Aug ’27US$47.30
US$59.31
+25.41%
8.51%US$70.00US$48.00n/a16
Jul ’27US$52.84
US$59.31
+12.25%
8.51%US$70.00US$48.00n/a16
Jun ’27US$47.39
US$59.31
+25.16%
8.51%US$70.00US$48.00n/a16
May ’27US$46.37
US$57.73
+24.51%
8.66%US$70.00US$48.00n/a15
Apr ’27US$49.35
US$57.43
+16.37%
8.77%US$70.00US$48.00n/a14
Mar ’27US$44.27
US$50.36
+13.75%
9.77%US$60.00US$42.00n/a14
Feb ’27US$44.34
US$50.36
+13.57%
9.77%US$60.00US$42.00n/a14
Jan ’27US$44.05
US$47.92
+8.78%
7.05%US$53.00US$42.00n/a12
Dec ’26US$41.99
US$47.33
+12.73%
6.81%US$53.00US$42.00n/a12
Nov ’26US$29.62
US$46.55
+57.14%
6.69%US$53.00US$43.00n/a11
Oct ’26US$34.68
US$47.80
+37.83%
7.93%US$54.00US$43.00n/a10
Sep ’26US$32.65
US$50.00
+53.14%
5.92%US$54.00US$45.00US$55.898
Aug ’26US$36.36
US$51.50
+41.64%
5.98%US$57.00US$46.00US$47.308
Jul ’26US$33.76
US$49.67
+47.12%
6.64%US$57.00US$45.00US$52.849
Jun ’26US$29.01
US$50.22
+73.12%
6.07%US$57.00US$45.00US$47.399
May ’26US$32.76
US$50.33
+53.64%
5.92%US$57.00US$45.00US$46.379
Apr ’26US$30.06
US$50.50
+68.00%
6.18%US$57.00US$45.00US$49.358
Mar ’26US$38.82
US$50.63
+30.41%
6.24%US$57.00US$45.00US$44.278
Feb ’26US$40.38
US$48.75
+20.73%
10.14%US$57.00US$39.00US$44.348
Jan ’26US$43.22
US$46.38
+7.30%
15.01%US$57.00US$33.00US$44.058
Dec ’25US$39.90
US$44.13
+10.59%
13.62%US$50.00US$33.00US$41.998
Nov ’25US$28.42
US$37.38
+31.51%
15.94%US$50.00US$30.00US$29.628
Oct ’25US$7.45
US$27.13
+264.09%
17.43%US$34.00US$20.00US$34.688
Sep ’25US$9.30
US$26.88
+188.98%
18.18%US$34.00US$20.00US$32.658
US$60.75
Fair Value
10.1% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 22:26
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scholar Rock Holding Corporation is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Etzer DaroutBarclays
Evan SeigermanBMO Capital Markets Equity Research